Rigel Pharmaceuticals Inc (RIGL)
20.83
+5.39
(+34.91%)
USD |
NASDAQ |
Nov 08, 13:56
Rigel Pharmaceuticals Revenue (TTM): 130.30M for June 30, 2024
Revenue (TTM) Chart
Historical Revenue (TTM) Data
Date | Value |
---|---|
June 30, 2024 | 130.30M |
March 31, 2024 | 120.35M |
December 31, 2023 | 116.88M |
September 30, 2023 | 132.37M |
June 30, 2023 | 126.64M |
March 31, 2023 | 129.58M |
December 31, 2022 | 120.24M |
September 30, 2022 | 89.37M |
June 30, 2022 | 88.51M |
March 31, 2022 | 84.95M |
December 31, 2021 | 149.24M |
September 30, 2021 | 147.28M |
June 30, 2021 | 144.12M |
March 31, 2021 | 133.88M |
December 31, 2020 | 108.62M |
September 30, 2020 | 105.57M |
June 30, 2020 | 108.04M |
March 31, 2020 | 102.42M |
December 31, 2019 | 59.29M |
September 30, 2019 | 81.74M |
June 30, 2019 | 65.75M |
March 31, 2019 | 57.13M |
December 31, 2018 | |
September 30, 2018 | |
June 30, 2018 |
Date | Value |
---|---|
March 31, 2018 | |
December 31, 2017 | |
September 30, 2017 | |
June 30, 2017 | |
March 31, 2017 | 18.94M |
December 31, 2016 | 20.38M |
September 30, 2016 | 25.92M |
June 30, 2016 | 35.16M |
March 31, 2016 | 31.75M |
December 31, 2015 | 28.90M |
September 30, 2015 | |
June 30, 2015 | |
March 31, 2015 | |
December 31, 2014 | |
September 30, 2014 | |
June 30, 2014 | |
March 31, 2014 | |
December 31, 2013 | |
September 30, 2013 | |
June 30, 2013 | |
March 31, 2013 | |
December 31, 2012 | |
September 30, 2012 | |
June 30, 2012 | |
March 31, 2012 |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (TTM) Range, Past 5 Years
59.29M
Minimum
Dec 2019
149.24M
Maximum
Dec 2021
115.67M
Average
120.24M
Median
Dec 2022
Revenue (TTM) Benchmarks
Ionis Pharmaceuticals Inc | 803.07M |
Collegium Pharmaceutical Inc | 576.65M |
NovaBay Pharmaceuticals Inc | 12.02M |
Palatin Technologies Inc | -- |
iBio Inc | -- |